BICD2 Mouse anti-Human, Rat, Clone: GT1824, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA527825
Positive Control: 293T, A431, HeLa, HepG2, PC-12, Rat2 Predicted Reactivity: Mouse (100%), Rhesus Monkey (100%), Bovine (100%) Store product as a concentrated solution. Centrifuge briefly prior to opening the vial. For short-term storage (1-2 weeks), product can be stored at 4°C. For long-term storage, aliquot and store product at -20° C or below, avioiding multiple freeze-thaw cycles.BICD2 is the second human homolog discovered to the Drosophila Bicaudal-D protein that forms part of the cytoskeleton and mediates the correct sorting of mRNAs for oocyte- and axis-determining factors during oogenesis. Similar to the highly homologous protein BICD1, BICD2 can bind to dynein-dynactin complex, primarily through the dynamitin subunit of dynactin. The C-terminus of BICD2 targets the protein to the Golgi complex while the N-terminal domain of BICD2 co-immunoprecipitates with cytoplasmic dynein, suggesting BICD2 plays a role in the dynein-dynactin interaction on the surface of membranous organelles. Mice engineered to overexpress the BICD2 amino terminal domain in neurons developed amyotrophic lateral sclerosis (ALS)-like features such as Golgi fragmentation, neurofilament swelling in proximal axons, etc., suggesting that impaired dynein/dynactin function may explain some of the pathological features observed in ALS patients.
|PBS with no preservative|
|bA526D8.1, bicaudal D homolog 2 (Drosophila)|
|Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Immunoprecipitation, Western Blot|
|Recombit protein encompassing a sequence within the N-terminus region of human BICD2. The exact sequence is proprietary.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok